Gastroenterology Approved Deal Benchmarks — Europe (2026)

Understanding Gastroenterology Deal Benchmarks at Approved

Approved Gastroenterology licensing deals in Europe territory command a median upfront payment of $990M, with values ranging from $725M at the low end to $1.2B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the gastroenterology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.0B to $2.7B, with a median of $2.4B. Royalty rates for gastroenterology assets at this stage typically fall between 9.9% and 17.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.